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Abstract. – OBJECTIVE: Technical success
of a finger replantation depends on several fac-
tors such as surgical procedure, type of injury,
number of segments amputated, amputation
level and individual patient factors. Among ear-
ly complications that can occur in this type of
surgery the onset of venous or arterial throm-
bosis is the most dreaded. Local irrigating so-
lutions, oral and intravenous anticoagulants,
thrombolytic agents, plasma expanders, vasodi-
lating, and antiaggregant drugs are routinely
used in patients undergoing microvascular pro-
cedures, but currently there is only a non-stan-
dardized practice based on anecdotal personal
experience.
MATERIALS AND METHODS: The aim of our
study is to review selected literature relating to
perioperative therapy in microsurgical digital re-
plantation. We also report our case-load of 16 pa-
tients with finger avulsion describing our particu-
lar protocol for postoperative anticoagulation and
restoration of fluid and electrolyte balance.
RESULTS: Following our daily pharmacologi-
cal protocol, the postoperative course of the re-
planted fingers was uneventful. The survival rate
for finger replantations performed was 100% (n =
16) with no need for surgical revisions.
CONCLUSIONS: The association Dextran-
40/Heparin/fluids in the proposed standardized
pro-weight pharmacological protocol is an opti-
mal postoperative prophylactic/therapeutic plan
to reduce the incidence of endovascular throm-
bosis after replantation, so ensuring high rate
of success in microvascular surgery.
Key Words:
Antithrombotic therapy, Digital replantation, Drug
therapy, Finger replantation, Postoperative care.
Introduction
The advent of microsurgical tissue transfer in-
cluding replantation greatly has expanded the
scope of reconstructive surgery to correct various
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congenital, ablative and traumatic defects. Hand
surgeons use microsurgical procedures to replant
amputated digits or repair injured nerves and
blood vessels. Since the first successful thumb
replantation by Komatsu and Tamai1, indications
for digital replantation have been narrowed and
surgical technique refined to maximize success
rate2,3. Survival of replanted digits has become
fairly reliable, with survival rates estimated to be
80% to 90% in the literature4-13. The advance-
ment of various free flap also helps in replanta-
tion surgery, e.g. crush injury across the wrist or
multiple fingers which may need replacement
with healthy tissue been the amputated digits and
wrist. Technical success of replantation depends
on several factors: certainly surgical proce-
dure10,14 and type of injury8,15,16 are the main prog-
nostic factors of the patency of microsurgical
anastomosis, but also other factors are involved
such as the number of segments amputated, the
amputation level and individual patient factors
(age, smoking, vascular disease)17. Early compli-
cations that can occur in this type of surgery are
the reduction of arterial perfusion caused by va-
sospasm or thrombosis, hemorrhage and venous
insufficiency18,19. Among them the onset of ve-
nous or arterial thrombosis remains the most
dreaded16,19, especially in the first 3 postoperative
days20. In fact the risk for thrombosis is highest
(80%) during the first 2 postoperative days and
decreases to 10% after postoperative day 321,22.
Zdeblick et al23 put forward the theory accord-
ing to which the suffering of endothelial cells of
the injured vessels leads to destruction of intercel-
lular junctions and formation of an intimal edema
causing the exposure of the sub-intimal collagen.
Contact of this collagen with blood cells and co-
agulation factors triggers the phenomenon of co-
agulation with formation of microthrombi which
2015; 19: 2552-2561
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Drug therapy after finger replantation
Patients Gender Age Smoking Type and mechanism Finger
(years) status of injury (R right hand,
L left hand) Complications
1 Female 35 Yes Knife cut III L No
2 Male 38 Yes Chainsaw amputation II R Local bleeding
3 Male 42 Yes Car stripping I R No
4 Male 50 Yes Door crush IV R No
5 Male 40 Yes Knife cut II R No
6 Male 32 No Ring avulsion amputation III R No
7 Male 34 No Knife cut I L No
8 Female 35 Yes Knife cut II R Dextran-40 allergic
reaction
9 Male 25 Yes Door stripping V R No
10 Female 38 Yes Knife cut II L No
11 Male 33 Yes Chainsaw amputation IV R No
12 Female 74 Yes Ring avulsion amputation IV L No
13 Female 28 No Glass amputation I R No
14 Male 31 No Knife cut II R No
15 Male 46 No Chainsaw amputation III R Local bleeding
16 Female 27 Yes Ring avulsion amputation IV L No
Table I. Patients characteristics
surgical digital replantation. We report our case-
load in 16 cases of finger avulsion describing our
particular protocol for postoperative anticoagula-
tion and restoration of fluid and electrolyte bal-
ance.
Patients and Methods
The study includes 16-microremplantations
of the upper limb performed between Septem-
ber 2011 and September 2013. Patients’ age
ranged between 25 and 50 years (the mean age
was 38), with 5 female and 11 males in the se-
ries. Eleven of the 16 patients were smokers
(Table I). All patients reported traumatic ampu-
tation of a single finger. So, after stabilization
of general clinical conditions, they underwent
replantation performing a microsurgical proce-
dure (Figures 1 to 3).
Postoperative Pharmacologic Protocol
After surgery, all the patients reported were in-
cluded in the following standardized pro-weight
pharmacological protocol, as shown in Table I:
• Fluids: 30-50 cc/kg/24h;
• Dextran-40 (molecular weight, 40 kd): 500
cc/24h;
• Heparin: 50-100 U/kg/24h intravenous.
This daily pharmacological protocol was car-
ried out for a period of 5 days postoperatively.
obliterate vascular lumen. Eriksson et al24 and
Marzella et al25 strengthened this theory demon-
strating that vascular obstruction occurs between
10 and 60 minutes following reperfusion after a
prolonged ischemia. Other authors suggest differ-
ent pathophysiological hypothesis to explain the
“phenomenon of non-vascularization” post-re-
plantation: Acland et al26,27 consider the responsi-
bility of arterial microanastomosis in the genesis
of platelet microemboli; Zamboni et al28,29 sup-
port inflammatory mechanisms.
Surgical intervention for thrombosis generally
involves anastomotic revision or interposition
vein grafting, but the occurrence of re-interven-
tion failure is high21,30, so the primary prevention
of thrombosis is of critical interest to microvas-
cular surgeons. Clinical and experimental data
suggest the benefit of perioperative antithrombot-
ic drug therapy in microvascular surgery and free
tissue transfer.
Several anti-coagulation and anti-platelet regi-
mens have been proposed to maintain micro-anas-
tomosis patency in the postoperative period, but a
unified algorithm does not exist among microsur-
geons regarding type, indications, timing and du-
ration of medication administration for digital re-
plantation-revascularization16,31,32. So currently
there is only a non-standardized practice based on
anecdotal personal experience9,16,33-35.
The aim of this study is to review selected lit-
erature relating to perioperative therapy in micro-
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Figure 1. Patient 34 years old with a knife cut injury with amputation of the distal phalanx of the thumb of the left hand (A);
distal phalanx (B).
Figure 2. Intraoperative view after replantation.
Results
The postoperative course of the replanted fin-
gers was uneventful. In fact, the survival rate for
finger replantations performed was 100% (n =
16), without the need for surgical revisions. No
case of necrosis was recorded. The complications
related with the antithrombotic medication were
almost irrelevant: there was only two cases of lo-
cal bleeding that required the suspension of he-
parin therapy for 24 hours; while another patient
manifested an allergic reaction to dextran-40 ne-
cessitating its definitive suspension.
Discussion
Recent reported failure rates in digital replan-
tation vary between 7% and 22%4-13, and this un-
toward event occurs mainly within the first 3
postoperative days16-22.
The most feared complication and a common
cause of digital replantation failure is vascular
thrombosis15. It is the result of alteration of Vir-
chow’s triad: in fact endothelial damage, due to
the direct action of the traumatic agent on vessel
wall, is combined with blood stasis and hyperco-
agulable state, due to the primer of repair mecha-
nisms.
Certainly, surgical technique and type/mech-
anism of injury are the main prognostic factors
of success or failure of finger replantation, but
also postoperative anti-thrombosis regimens
are of prime importance in the prevention of
thrombosis.
Local irrigating solutions, oral and intravenous
anticoagulants, thrombolytic agents, plasma ex-
panders, vasodilating, and antiaggregant drugs
are routinely used in patients undergoing mi-
crovascular procedures. However, it is still a mat-
ter of debate for the most beneficial agent (or
combination of agents), and the optimal time to
start or end their administration. This has led to
non-standardized practice based on anecdotal ex-
perience.
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Drug therapy after finger replantation
Figure 3. Post-operative view after 1 month.
temically administered intravenous heparin or
dextran-40. In other studies systemic heparin
provided greater protection against rethrombosis
after the repair of a thrombosed anastomosis52,53.
Stockmans et al45 showed that heparin, when ad-
ministrated systemically to a therapeutic level re-
duces the rate of primary venous thrombosis by
60% whereas higher doses result in close to a
100% reduction. Hudson et al54 used an in situ
venous catheter inserting it proximal to the ve-
nous anastomosis to deliver high local doses oh
heparin while maintaining low systemic levels,
thus reporting satisfactory outcomes. Recently
topical antithrombotic administration has been
suggested as an alternate approach to local anti-
coagulation36,55-59, but results are controversial.
Fu et al60 reported that topical administration of
heparin results in 80% patency at the anastomo-
sis sites, while Khouri et al61 did not observe a
benefit to using intraluminal heparin irrigation in
reducing postoperative thrombosis. In fact, this
procedure may increase vessel patency but the
direct effect of the pressure can injure the vessel
with a detrimental effect on microvascular anas-
tomoses62.
Low Molecular Weight Heparins (LMWH)
LMWH is a derivative of unfractionated he-
parin, prepared through the deaminative hydroly-
sis of standard heparin into short polysaccharide
fragments. It has the same inhibitory effect on
active factor X but has a weaker antithrombin
(factor II) activity. So it results effective in pre-
venting venous thrombosis with fewer adverse
effects63-65. Instead, the efficacy of LMWH to
prevent arterial thrombosis is a point of debate.
Some studies found LMWH to be a less effective
treatment than traditional heparin in reducing the
frequency of arterial thrombosis66,67, while others
have reported better or equal results65,68. The pro-
tective effects of LMWH also include antithrom-
bin-independent effects such as the release of tis-
sue factor pathway inhibitor, interactions with
heparin cofactor II, and platelet factor 464. There-
fore, attempts to standardize LMWHs on the ba-
sis of anti-Xa activity have not been completely
successful. This explains the inherent difficulty
in determining equivalent doses of unfractionated
heparin to LMWHs. The pharmacologic profiles
and efficacies of LMWHs vary; therefore, suc-
cess with one LMWH at a certain dose does not
generalize to the whole group. Similar to unfrac-
tionated heparin the application of topical
LMWH minimizes systemic side effects69.
Antithrombotic Therapy
Optimal antithrombotic therapy should target
the coagulation cascade as well as platelet aggre-
gation as their mechanisms appear to be syner-
getic36-40.
Heparin (Heparin IV, Heparin SC)
Heparin has been used clinically for more than
50 years and it’s currently the anticoagulant
agent used most widely by surgeons to prevent
both arterial and venous thrombosis. It is a
polyglycosaminoglycan of varying lengths, that
binds to antithrombin III enhancing its antipro-
tease activity and accelerating its attachment to
its substrate approximately 1000-fold. As a result
the active forms of coagulation factors II (throm-
bin), IX, X, XI, and XII are rendered inactive and
the clotting cascade is impaired41. Through inhi-
bition of thrombin generation heparin reduces the
activation of coagulation factors V and VIII, re-
cruitment of platelets, and formation of fibrin42,43.
Moreover, large doses of heparin result in vasodi-
lation that possibly is mediated by the release of
nitric oxide from the endothelium44. The goal in
heparin therapy is the efficient delivery of a mini-
mal therapeutic dose to the site of vascular anas-
tomosis. Maintaining low systemic heparin levels
minimizes its adverse effects of anticoagulation
mainly represented by hemorrhage from the sur-
gical site45, formation of hematoma46,47, and also
heparin-induced thrombocytopenia (HIT)48-50.
Rooks et al51 reported no significant difference
in the protective effect of intra-arterial and sys-
Dextran
Dextrans are a group of variously sized poly-
saccharides that are synthesized from sucrose by
Leuconostoc mesenteroides streptococcus. The
antithrombotic effect of dextran is mediated
through its binding to erythrocytes, platelets, and
vascular endothelium, increasing their elec-
tronegativity and, thus, reducing erythrocyte ag-
gregation and platelet adhesiveness through de-
crease of factor VIII-Ag (von Willebrand’s fac-
tor). Platelets coated in dextran are distributed
more evenly in a thrombus and are bound by
coarser fibrin, which simplifies thrombolysis70,71.
By inhibiting α-2 antiplasmin, dextran also
serves as a plasminogen activator in thromboly-
sis. In addition, larger dextrans that remain in
blood vessels act as potent osmotic agents to re-
verse hypovolemia72,73. Volume expansion causes
hemodilution and this improves blood flow and
further increases patency of microanastomosis.
For these properties dextrans are used commonly
by microsurgeons to decrease vascular thrombo-
sis74. No difference has been observed in the an-
tithrombotic efficacy of intra-arterial versus in-
travenous dextran administration51. The varying
size of dextran, from 10 to 150 kd, results in pro-
longed antithrombotic and colloidal effects72.
Larger dextrans are excreted poorly from the kid-
ney and remain in the blood for weeks until they
are metabolized75. The most popular dextran for
anticoagulation is Dextran-40 (molecular weight,
40 kd). Close to 70% of it is excreted in the urine
within the first 24 hours after intravenous infu-
sion and the remaining 30% is retained for sever-
al more days, prolonging its effects76,77. Side ef-
fects associated with dextran use are relatively
few but they can be very serious, such as anaphy-
laxis, volume overload, pulmonary edema, cere-
bral edema, platelet dysfunction, or acute renal
failure.
Aspirin (ASA)
Aspirin (acetylsalicylic acid, ASA) acetylates
and inhibits the platelet enzyme cyclooxygenase,
impeding arachidonic acid breakdown to throm-
boxane and prostacyclin. Thromboxane is a po-
tent vasoconstrictor that induces platelet aggrega-
tion and prostacyclin is a vasodilator that inhibits
platelet aggregation. There is evidence that as-
pirin impairs thrombin generation and reactions
catalyzed by this enzyme at the site of anastomo-
sis78. Reconstructive surgeons frequently use as-
pirin in the perioperative period to improve flap
survival. In fact, perioperative administration of
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aspirin is known to prevent microvascular throm-
bosis at both anastomoses sites79,80, although it is
less effective than heparin52,81-83. However, the
protective effect of aspirin increases when co-ad-
ministered during surgery with another an-
tiplatelet agent84,85. Many surgeons prefer low-
dose aspirin because it does not affect endothelial
and smooth muscle cyclooxygenase. As a result
prostaglandin I2 (platelet antagonist and vasodila-
tor) production is unaffected and there are fewer
systemic side effects86. Unfortunately, the same
mechanisms that make aspirin a powerful an-
tithrombotic tool also can cause major problems.
In fact, platelet dysfunction results in increased
blood loss during surgery, which increases trans-
fusion and re-operation rates87. Other aspirin side
effects stem from its nonselective inhibition of
cyclooxygenase, such as serious renal dysfunc-
tion or gastrointestinal bleeding. Howevers, these
risks are dose dependent and a low-dose regimen
(75 mg/d) minimizes them88.
Thrombolytics (Streptokinase, Urokinase,
Tissue-type Plasminogen Activator)
Thrombolytic agents available for clinical use
include streptokinase, urokinase89, and tissue-
type plasminogen activator (recombinant tissue
plasminogen activator, rt-PA)90-92. Their efficacy
in reversing microvascular thrombosis is well
documented in the animal model93,94, instead
most human studies look at small study popula-
tions and so there’re no definitive conclusions on
the relative efficacy and appropriate dosing of
thrombolytics. However, Rooks et al51 reported
satisfactory results and they demonstrated, for an
established thrombus, an advantage to intra-arter-
ial over intravenous administration of throm-
bolytics because intra-arterially delivered uroki-
nase results in significantly greater efficacy
(100% for intra-arterial vs 40% intravenous).
Thrombolytic agents are associated with a risk
for bleeding but this risk can be minimized by
draining the venous effluent to prevent systemic
exposure to the agent95. After using thrombolytic
agents hematoma should be checked to prevent
compression to the vessels.
Prostaglandin E1
Medical scientists continue to search for new
antithrombotic and anticoagulant therapies that
maximize benefits while minimizing adverse ef-
fects. Between new therapies there is
Prostaglandin E1 (PGE1)96. This molecule has
been used for many years in the treatment of
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claudication97-98, peripheral arterial occlusive dis-
ease99, Raynaud’s syndrome100-101, and as adjuvant
treatment after profundaplasty. In fact, PGE1 has
multiple effects on the microcirculatory level
with relevant vasodilating, antithrombotic and
anti-ischemic properties and it also have anti-in-
flammatory effects inhibiting monocyte and neu-
trophil function. Many authors demonstrated that
PGE1 is effective in the prevention and resolu-
tion of microvascular spasm, a complication
which can be a major issue after prolonged is-
chemia (replantations)96,102-104. However, its over-
all clinical efficacy and safety in microvascular
surgery remains to be determined in larger,
prospective clinical trials.
As reported in the literature, the antithrombot-
ic drugs most commonly used in digital replanta-
tion/revascularization are the following: Aspirin
(Acetylsalicylic Acid, ASA), with a dosage of
180-325 mg; Heparin (Heparin IV/Heparin SC,
unfractionated; or Low Molecular Weight He-
parins, LMWH, fractionated); and Dextran (plas-
ma expander).
Instead our postoperative pharmacological
protocol consisted in daily intravenous standard-
ized pro-weight administration of heparin, dex-
tran and fluids, in the first 5 postoperative days,
which is the time interval within which the inci-
dence of thrombosis is usually high.
The rational use of this pharmacological pro-
tocol is explained by synergic action of these
drugs on the different components of Virchow’s
triad, thus, reducing the risk of intravascular
thrombosis.
In particular our goal was based on four key
points, as follows: to obtain an anticoagulant ef-
fect (1) and an antithrombotic effect (2); to
achieve an effective reduction in hematocrit up to
a minimum value of 27-28% (3); to reduce en-
dothelial damage (4).
In fact, the synergistic action of heparin (in-
hibitory effect on coagulation cascade) with dex-
tran (inhibitory effect on platelet aggregation) in-
volves an effective improvement of the hyperco-
agulable state, which typically occurs as a de-
fense mechanism in response to injury.
Blood fluidification and consequently slowing
of the flow are achieved also thanks to continu-
ous administration of postoperative fluids (plas-
ma expander effect) with the aim to reduce
hematocrit up to very low values.
Finally, a further strength of our therapeutic
strategy in the medical approach to fingers ampu-
tation is certainly represented by rapidity of
restoration of the vascular wall integrity. It is ob-
tained by the most advanced microsurgical pro-
cedures/techniques which optimally allow to pull
over damaged endothelial cells to each other. In
fact, no anticoagulant or other medications can
replace a perfect anastomosis. However, after
trauma the success of replantation can be im-
proved by adding medication to the perfect anas-
tomoses.
In addition, regarding the possible complica-
tions related with the proposed antithrombotic
medication, we affirmed that the association of
different drugs (Dextran and Heparin) did not in-
crease the postoperative bleeding, as reported in
our series.
Conclusions
We suggest our standardized pro-weight phar-
macological protocol as an optimal postoperative
prophylactic/therapeutic plan to reduce the oc-
currence of endovascular thrombosis after re-
plantation and therefore to ensure high rate of
success in microvascular surgery.
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